Information Provided By: 
Fly News Breaks for September 19, 2016
SRPT, BMRN
Sep 19, 2016 | 12:19 EDT
Raymond James analyst Christopher Raymond noted that the FDA approval of Sarepta's (SRPT) eteplirsen for the treatment of exon 51 skipping amenable Duchenne's muscular dystrophy opens up an "unexpected potential revenue stream" for BioMarin (BMRN), which he said currently holds a "dominant patent position" on Exon 51 skipping therapies. The analyst, who thinks BioMarin may stand to benefit from Sarepta's news, keeps an Outperform rating on BioMarin shares.
News For BMRN;SRPT From the Last 2 Days
